<DOC>
	<DOCNO>NCT01348347</DOCNO>
	<brief_summary>This open-label phase I dose escalation trial , 1230.15 , first trial Volasertib Japanese advance cancer patient . The trial investigate maximum tolerate dose ( MTD ) , safety , tolerability , preliminary efficacy specific polo-like kinase 1 ( Plk1 ) inhibitor advance cancer patient .</brief_summary>
	<brief_title>BI 6727 ( Volasertib ) Monotherapy Phase I Trial Japanese Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Patients histologically cytologically confirm accord discretion investigator 2 . Patients advance , nonresectable and/or metastatic solid tumour accord discretion investigator 3 . Patients fail conventional treatment , therapy prove efficacy exists , amenable establish form treatment accord discretion investigator 4 . Age &gt; =20 year old time inform consent 5 . Written inform consent 6 . Life expectancy least 12 week accord discretion investigator 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 8 . Recovery Common Terminology Criteria Adverse Events ( CTCAE ) grade =1 therapyrelated toxicity previous chemo , hormonal , immuno , radiotherapy ( except alopecia hyperpigmentation ) 9 . Adequate bone marrow , renal hepatic function ; Neutrophil count : 1500/mm3 Platelet count : 100 000/mm3 Haemoglobin : 9.0 g/dL Total bilirubin : le 1.5 time upper limit normal ( ULN ) Aspartate amino transferase ( AST ) : le 2.5 × ULN Alanine amino transferase ( ALT ) : le 2.5 × ULN Serum creatinine : le 1.5 × ULN 10 . Patients hospitalise first course Exclusion criterion : 1 . Major surgery within 4 week prior registration side effects/toxicities surgery recover CTCAE grade =1 2 . Known seropositivity human immunodeficiency virus ( HIV ) antibody , hepatitis B antigen hepatitis C antibody 3 . Accumulation coelomic fluid ( e.g . pleural effusion , ascites fluid ) require treatment trial ( Patients eligible treat curatively evidence recurrence . ) 4 . Current symptomatic brain metastasis patient require treatment brain metastases 5 . Previous double cancer . Other tumour ( except noninvasive and/or nonmelanomatous skin cancer , completely remove situ carcinoma epithelium mucosa ) treat curatively evidence recurrence least 5 year prior initial study treatment eligible . 6 . Known history cardiac dysfunction ; Correction QT interval accord Fridericias formula ( QTc ) 470 ms History unstable angina pectoris within 6 month current unstable angina pectoris History myocardial infarction within 6 month Arrhythmia currently require active therapy Previous current cardiac failure History clinically significant cardiac disease accord discretion investigator 7 . Pregnant breastfeed woman 8 . Women men sexually active unwilling use medically acceptable method contraception ( e.g . implant , injectables , combine oral contraceptive , intrauterine device , vasectomise partner , condom ) trial least 6 month end active therapy . Women sexually active premenopausal female patient . Premenopausal female patient define patient observed menses within 12 month except alternative medical cause . Women underwent operation sterilisation exclude criterion . 9 . Treatment investigational drug within past 4 week registration concomitantly trial ( except present trial drug ) 10 . Chemo , radio , immuno , moleculartargeted therapy within past 4 week registration concomitantly trial . This restriction apply bisphosphonates . 11 . Patients unable comply protocol accord discretion investigator subinvestigators 12 . Current alcohol abuse drug abuse accord discretion investigator 13 . Patients inappropriate trial discretion investigator subinvestigators ( e.g . uncontrolled diabetes mellitus , evidence serious active infection , medically significant abnormal laboratory finding , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>